Technology

Technology is at the heart of our team's passion.

Our first two FDA-cleared products, the T2Candida Panel and T2Dx Instrument, use T2MR technology to accurately detect Candida – a sepsis-causing bloodstream infection – in an average of 4.3 hours with no blood culture. This rapid detection can help physicians to lower Candida’s 40% mortality rate to 11%.1,2 And this is only the beginning. We are developing products for rapid bacteria detection and hemostasis measurements, which could impact over 11 million patients. We’ve also entered into a partnership with Canon U.S. Life Sciences to improve the detecton of Lyme disease-causing pathogens – a debilitating disease where 3.4 million tests are performed on patients annually.  

Learn more about our culture of innovation and collaboration.

 

 ______________________________

1. Morrell, M., Fraser, V. J., and Kollef, M. H. (2005). Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortalityAntimicrobial agents and chemotherapy, 49(9), 3640-3645. 
2. Garey, K. W., Rege, M., Pai, M. P., et. al. (2006). Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional studyClinical infectious diseases, 43(1), 25-31.